Considering that NF-κB is activated by epidermal growth factor receptors (EGFR) [13], the amplification of the EGFR gene HER2/ERBB2/neu in a significant fraction of human breast cancers [50] may provide a partial explanation for downregulation of KLF2 in breast tumors. This evidence concerns the gene EGFR and breast carcinoma.